AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Hepatocellular carcinoma: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaNCT02678572 · results posted 2026-09-10 · Delcath Systems Inc. · 102 people · tests Melphalan/HDS Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)NCT04246177 · results posted 2026-09-03 · Merck Sharp & Dohme LLC · 480 people · tests Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaNCT04194775 · results posted 2026-07-30 · CStone Pharmaceuticals · 534 people · tests Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)NCT03867084 · results posted 2026-04-24 · Merck Sharp & Dohme LLC · 959 people · tests Pembrolizumab, Placebo Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791 · results posted 2025-12-11 · Exelixis · 837 people · tests Cabozantinib, Cabozantinib, Sorafenib, Atezolizumab
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
New liver cancer medicine fast-tracked by UK Government.Lancet Oncol 2026 · PMID 42594924 Spatiotemporal multiomics uncover tumor ecosystem dynamics during metastatic colonization.Science 2026 · PMID 42531396 Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial.JAMA Oncol 2026 · PMID 42530948 Cancer Type-Specific Contributions to the Reduction in Cancer Mortality Gap Between Black Individuals and White Individuals.JAMA Oncol 2026 · PMID 42461622 Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.JAMA Oncol 2026 · PMID 42390849 Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.Nat Rev Clin Oncol 2026 · PMID 42270817 Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcome…J Clin Oncol 2026 · PMID 42139645 TMEM87A suppresses ferroptosis and increases cancer immunotherapy resistance by maintaining the Golgi apparatus pH homeostasis.Nat Cancer 2026 · PMID 42014864 scSurvival: Single-Cell Survival Analysis of Clinical Cancer Cohort Data at Cellular Resolution.Cancer Discov 2026 · PMID 42013315 Hallmarks of liver cancer: Therapeutic implications.Cell 2026 · PMID 41997132 A confidence-based, artificial intelligence pathology model for diagnosis of intrahepatic cholangiocarcinoma.Ann Oncol 2026 · PMID 41791652 Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005)…J Clin Oncol 2026 · PMID 41734362
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA

No label updates found.

An update is not always a new approval — open the label to see what changed.

Want these every week? Follow hepatocellular carcinoma and get a note on your phone with the new trials and papers.

🔔 Follow hepatocellular carcinoma
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy